Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Circadian Therapeutics, a life sciences spinout of Oxford University, has been established to identify and bring to market pharmaceutical and diagnostic platforms for the effective management of physiological and pathological conditions through their ability to modify the body's circadian rhythms.

Alarm clock on a bed © Pollar SD - Shutterstock

Today, there are no safe, effective and fast-acting treatments that provide benefit to patients through modulation of circadian rhythms.

To address this, Circadian Therapeutics has identified drug candidates and is looking to study their effects on circadian rhythms in clinical trials. Simultaneously, the company is aiming to replace hospital-based, expensive diagnostics through the development of a home-based ambulatory electroencephalogram (EEG) device that will provide accurate and minimally intrusive measurement of brain function and circadian rhythms. The home-based monitoring of patients is vastly more cost effective and enables patient monitoring at scale, allowing for more precise and personalised medication. The combination of such products and technologies could be used for interventions across the health spectrum.

Read more

Similar stories

Risk of rare blood clotting higher for COVID-19 than for vaccines

Coronavirus COVID-19 Research

COVID-19 leads to a several-times higher risk of cerebral venous thrombosis (CVT) blood clots than current COVID-19 vaccines.

Alternating vaccines trial expands to include two additional vaccines

Clinical Trials Coronavirus COVID-19 General

Researchers running the Com-Cov study, launched in February to investigate alternating doses of the Oxford-AstraZeneca vaccine and the Pfizer vaccine, have today announced that the programme will be extended to include the Moderna and Novavax vaccines in a new study.

Asthma drug budesonide shortens recovery time in non-hospitalised patients with COVID-19

Clinical Trials Coronavirus COVID-19 Research

Inhaled budesonide, a common corticosteroid, is the first widely available, inexpensive drug found to shorten recovery times in COVID-19 patients aged over 50 who are treated at home and in other community settings, reports the PRINCIPLE trial in 1,779 participants.

Link between COVID-19 infection and subsequent mental health and neurological conditions found

Coronavirus COVID-19 General Research

One in three COVID-19 survivors received a neurological or psychiatric diagnosis within six months of infection with the SARS-CoV-2 virus, an observational study of more than 230,000 patient health records published in The Lancet Psychiatry journal estimates. The study looked at 14 neurological and mental health disorders.

New national study of long-term impacts of debilitating lung damage from COVID-19

Coronavirus COVID-19 General Research

A new national study will investigate the long-term effects of lung inflammation and scarring from COVID-19. The study, launched with £2 million of funding from UK Research and Innovation (UKRI), aims to develop treatment strategies and prevent disability.